My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 144

    1.

    Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients.

    Jabri N, Schalch DS, Schwartz SL, Fischer JS, Kipnes MS, Radnik BJ, Turman NJ, Marcsisin VS, Guler HP.

    Diabetes. 1994 Mar;43(3):369-74.PMID: 8314009 [PubMed - indexed for MEDLINE]Related articles

    2.

    Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus.

    Schalch DS, Turman NJ, Marcsisin VS, Heffernan M, Guler HP.

    J Clin Endocrinol Metab. 1993 Dec;77(6):1563-8.PMID: 8263142 [PubMed - indexed for MEDLINE]Related articles

    3.

    Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.

    Clemmons DR, Sleevi M, Allan G, Sommer A.

    J Clin Endocrinol Metab. 2007 Jul;92(7):2652-8. Epub 2007 Apr 10.PMID: 17426090 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes.

    Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR.

    Diabetes. 1996 Jan;45(1):91-100.PMID: 8522066 [PubMed - indexed for MEDLINE]Related articles

    5.

    Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus.

    Vestergaard H, Rossen M, Urhammer SA, Müller J, Pedersen O.

    Eur J Endocrinol. 1997 May;136(5):475-82.PMID: 9186267 [PubMed - indexed for MEDLINE]Related articles

    6.

    Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group.

    Thrailkill KM, Quattrin T, Baker L, Kuntze JE, Compton PG, Martha PM Jr.

    Diabetes Care. 1999 Apr;22(4):585-92.PMID: 10189536 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance.

    Cusi K, DeFronzo R.

    J Clin Endocrinol Metab. 2000 Sep;85(9):3077-84.PMID: 10999789 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.

    Clemmons DR, Moses AC, Sommer A, Jacobson W, Rogol AD, Sleevi MR, Allan G.

    Growth Horm IGF Res. 2005 Aug;15(4):265-74.PMID: 16005252 [PubMed - indexed for MEDLINE]Related articles

    9.

    Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.

    Carroll PV, Umpleby M, Alexander EL, Egel VA, Callison KV, Sönksen PH, Russell-Jones DL.

    Clin Endocrinol (Oxf). 1998 Dec;49(6):739-46.PMID: 10209561 [PubMed - indexed for MEDLINE]Related articles

    10.

    Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance.

    Morrow LA, O'Brien MB, Moller DE, Flier JS, Moses AC.

    J Clin Endocrinol Metab. 1994 Jul;79(1):205-10.PMID: 8027228 [PubMed - indexed for MEDLINE]Related articles

    11.

    Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus.

    Zenobi PD, Jaeggi-Groisman SE, Riesen WF, Røder ME, Froesch ER.

    J Clin Invest. 1992 Dec;90(6):2234-41.PMID: 1469083 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus.

    Pennisi P, Gavrilova O, Setser-Portas J, Jou W, Santopietro S, Clemmons D, Yakar S, LeRoith D.

    Endocrinology. 2006 Jun;147(6):2619-30. Epub 2006 Mar 2.PMID: 16513827 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.

    Camacho-Hübner C, Rose S, Preece MA, Sleevi M, Storr HL, Miraki-Moud F, Minuto F, Frystyk J, Rogol A, Allan G, Sommer A, Savage MO.

    J Clin Endocrinol Metab. 2006 Apr;91(4):1246-53. Epub 2006 Jan 10.PMID: 16403822 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Therapeutic potential of insulin-like growth factor-1 in patients with diabetes mellitus.

    Mohamed-Ali V, Pinkney J.

    Treat Endocrinol. 2002;1(6):399-410. Review.PMID: 15832492 [PubMed - indexed for MEDLINE]Related articles

    15.

    The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.

    Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J.

    J Clin Endocrinol Metab. 2000 Apr;85(4):1518-24.PMID: 10770191 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    [Biological and clinical analyses of the mechanism of growth retardation and the effect of recombinant human insulin-like growth factor-1 (rhIGF-1) treatment on glucose metabolism and growth in leprechaunism with severe insulin resistant diabetes]

    Kato M.

    Hokkaido Igaku Zasshi. 1998 Nov;73(6):613-25. Japanese. PMID: 10036618 [PubMed - indexed for MEDLINE]Related articles

    17.

    High dose intravenous, but not low dose subcutaneous, insulin-like growth factor-I therapy induces sustained insulin sensitivity in severely resistant type I diabetes mellitus.

    Usala AL, Madigan T, Burguera B, Cefalu W, Sinha MK, Powell JG, Usala SJ.

    J Clin Endocrinol Metab. 1994 Aug;79(2):435-40.PMID: 8045959 [PubMed - indexed for MEDLINE]Related articles

    18.

    Does recombinant human insulin-like growth factor-1 have a role in the treatment of diabetes?

    Dunger DB, Acerini CL.

    Diabet Med. 1997 Sep;14(9):723-31. Review.PMID: 9300221 [PubMed - indexed for MEDLINE]Related articles

    19.

    Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism.

    Nakae J, Kato M, Murashita M, Shinohara N, Tajima T, Fujieda K.

    J Clin Endocrinol Metab. 1998 Feb;83(2):542-9.PMID: 9467572 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Side effects resulting from the use of growth hormone and insulin-like growth factor-I as combined therapy to frail elderly patients.

    Sullivan DH, Carter WJ, Warr WR, Williams LH.

    J Gerontol A Biol Sci Med Sci. 1998 May;53(3):M183-7.PMID: 9597049 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity